Sorin Group, (Reuters Code: SORN.MI), a global medical device company
and a leader in the treatment of cardiovascular diseases, announced
today at Heart Rhythm 2012, the Heart Rhythm Society's 33rd
Annual Scientific Sessions, FDA approval and commercial launch for a
full portfolio of pacing, defibrillation and left ventricular leads.
Designed for effective electrical performance and durability, each of
the three lead series - TILDA pacing leads, VIGILA defibrillation leads
and CELERITY left ventricular leads - include multiple sizes and
features to enable physicians to match their implant preferences with
individual patient needs.
In addition to a flexible silicone lead body, steroid eluting tips that
reduce inflammation, and iridium fractal coated electrodes with proven
electrical performance, each lead family offers its own
additional features:
-
TILDA pacing leads include a flexible lead body and distal tip and are
designed for easy implantation and predictable performance.
-
VIGILA defibrillation leads feature a symmetrical lead body and thick
outer insulation. Convex shock coils embedded in silicone insulation
are engineered to minimize tissue in-growth.
-
CELERITY left ventricular leads have a flexible co-radial body, and
are designed to facilitate access and ensure stability in targeted
pacing sites regardless of patients' coronary venous anatomies.
"Sorin Group is bringing important new implantable heart rhythm and
heart failure systems to the United States, an important and growing
market for Sorin Group. The VIGILA, TILDA and CELERITY leads are
important additions that will help the U.S. physicians manage their
patients," said Stefano Di Lullo, Sorin Group, President of the CRM
Business Unit. "We've received tremendous feedback from physicians in
other international markets about the reliability of these leads, and we
are committed to continuing to deliver outstanding technologies to
enhance clinical performance and patient outcomes in the United States
and throughout the world."